Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use REPATHA® safely and effectively. See full prescribing information for REPATHA. REPATHA (evolocumab) injection, for subcutaneous use Initial U.S. Approval: 2015
Medication labelWhy this: Advisory · dailymed-prescription
REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events. As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
- generic_name
- evolocumab
- product_names
- Evolocumab
- ndc
- 72511-760, 72511-760-01, 72511-760-02, 72511-760-91, 72511-750, 72511-750-01, 72511-770, 72511-770-01, 72511-770-91, 72511-393, 72511-393-02, 72511-393-01, 72511-393-96, 72511-501, 72511-501-01, 72511-143, 72511-143-02, 72511-143-96, 72511-143-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en